International Journal of Molecular Sciences
December 28, 2025
Mateusz Kowalczyk, David Aebisher, Jakub Szpara et al.
3 citations
Depression is a common, debilitating, and potentially life-threatening mental disorder affecting individuals across all age groups and populations. It represents one of the major challenges of contemporary medicine. It is estimated that more than 300 million people worldwide are affected, and patients with major depressive disorder (MDD) exhibit a significantly increased risk of suicide,...
Complementary Therapies in Clinical Practice
December 23, 2025
Naomi E. Clark, Ben Parkinson, Xu Wang et al.
Post-stroke anxiety and depression symptoms are common after stroke and can persist long-term. Despite this, there is a lack of long-term psychological support for post-stroke anxiety and depression. Mindfulness-based interventions are emerging as feasible, acceptable and potentially effective interventions for post-stroke anxiety and depression. Sustained use of mindfulness practice can help...
JPMA. The Journal of the Pakistan Medical Association
December 20, 2025
Muhammad Bin Mobin, Zainab Abid, Sameen Saqib
Borderline Personality Disorder (BPD) is characterised by altered perception of self, mood changes, and suicidal ideation. The traditional treatments of BPD, including psychotherapy, fail to provide an immediate response in susceptible patients. However, recent literature has shed light on the use of Ketamine as intervention for suicidal ideation in BPD patients, as well as for patients with...
December 15, 2025
Lindsey Elise Wade
Depression is one of the most prevalent and burdensome mental health conditions worldwide, affecting millions and contributing to over 700,000 deaths by suicide annually. Nearly half of patients with major depressive disorder fail to respond adequately to standard antidepressant treatments such as selective serotonin reuptake inhibitors (SSRIs). Psilocybin-assisted therapy (PAT) has emerged as...
Narra J
December 1, 2025
Alla Glushich, Justin DeMaranville, Tinakon Wongpakaran et al.
Depression is prevalent among older adults in Southeast Asia, with fear of death as a key contributing factor. In Thailand, Buddhist death contemplation practices promote acceptance of mortality and may support mental well-being. However, their impact on mental health among elderly Thai Buddhist meditation practitioners remains underexplored. The aim of this study was to examine the...
JAACAP open
December 1, 2025
Tram N B Nguyen, Benjamin A Ely, Aria Vitale et al.
Youth with depression use cannabis at high rates, and exposure to cannabinoids in adolescence has been shown to deleteriously alter the reward system. However, there has been sparse research on the link between adolescent cannabis use and anhedonia, a core symptom of depression and clinical manifestation of reward dysfunction. Here, in a sample of adolescents presenting predominantly with mood...
Journal of Medical Regulation
December 1, 2025
Amol Soin, Y.c. Janardhan Reddy, Kris Ferguson et al.
ABSTRACT: Ketamine is an N-methyl-D-aspartate (NMDA) receptor antagonist that has been approved for use as a clinical and veterinary anesthetic since 1970. Although esketamine, a specific molecular form of ketamine, is FDA-approved for the management of treatment-resistant depression, regular ketamine is often used off-label at subanesthetic doses to treat depression as well as other...
Alpha psychiatry
December 1, 2025
Samantha Knep, Alice Shires
1 citation
This systematic review aimed to investigate the effectiveness of mindfulness-based interventions (MBIs) in treating depression, enhancing interoceptive awareness (IA), and whether IA mediates this relationship. In August 2024, a comprehensive literature search was conducted in web-based medical and psychological databases, including PsycINFO, MEDLINE, and Scopus, following the Preferred...
Cureus
December 1, 2025
Paweł Liszka, Agata Ogórek, Klaudia M Olejnik-Chlewicka et al.
Classic psychedelics and related substances, such as 3,4-methylenedioxymethamphetamine (MDMA), have again become a focus of interest in psychiatry as potential therapeutic tools. The aim of this paper is to review current data on their mechanisms of action, clinical applications in the treatment of mood and anxiety disorders, addictions and post-traumatic stress disorder (PTSD), as well as to...
European Journal of Psychotraumatology
December 1, 2025
Gabrielle Agin-Liebes, Richard J. Zeifman, Jennifer Mitchell
11 citations
Background: Posttraumatic stress disorder (PTSD) is a severe condition often complicated by co-occurring disorders, such as major depression, alcohol use disorder, and substance use disorders. A well-powered phase 3 randomized, placebo-controlled trial has shown that MDMA-assisted therapy (MDMA-AT) may be an effective treatment for severe PTSD. However, the psychological mechanisms driving the...